Results 41 to 50 of about 36,390 (302)
Targeting eosinophils: severe asthma and beyond
Drugs in Context, 2019 Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma ...
Marco, Francesco, Lucia, Gianenrico
doaj +1 more source
Successful treatment with dupilumab for mucus plugs in severe asthma
Respirology Case Reports, 2023 A 29‐year‐old man presented to our hospital with severe eosinophilic asthma. He needed a short OCS burst for exacerbation of asthma once every 1 or 2 months, although he used a high dose of inhaled corticosteroids and a long‐acting beta‐2 agonists. Chest
Moriyasu Anai +7 more
doaj +1 more source
Conducting retrospective impact analysis to inform a medical research charity’s funding strategies: The case of Asthma UK [PDF]
, 2013 © 2013 Hanney et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and ...
Amanda Watt +7 more
core +1 more source
Eosinophil trafficking in asthma [PDF]
Clinical Medicine, 2001 Asthma is characterised by a 50-fold increase in the number of eosinophils relative to neutrophils in the bronchial mucosa. This is the result of the cumulative and sequential effects of several, approximately fourfold, increases in selective eosinophil versus neutrophil migration occurring at a number of stages in the life cycle of the eosinophil ...
openaire +2 more sources
Pharmaceutics, 2023 The role of type 2 inflammation has been progressively associated with many diseases, including severe asthma, atopic dermatitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis, and, recently, eosinophilic esophagitis.
Diego Bagnasco +7 more
doaj +1 more source
Airway wall remodeling in asthma : novel mechanisms of human bronchial smooth muscle cells in the induction of angiogenesis [PDF]
, 2014 Asthma is a global major health concern and it affects estimated 300 million people. The prevalence of asthma is rising and there is no cure for asthma, only the symptoms can be controlled.
Keglowich, Laura Franziska
core +1 more source
Editorial : experimental models of asthma
, 2008 Since 2002, a workshop entitled “Asthma in animal models” has been held once a year in Hannover, Germany. It is organized by the Fraunhofer Institute of Toxicology and Experimental Medicine in collaboration with the collaborative research centre ...
Thomas Tschernig +5 more
core +1 more source
Allergy, Asthma & Clinical Immunology, 2011 This case reports the unique association of eosinophilic gastrointestinal disease with eosinophilic bronchitis, asthma and chronic rhinosinusitis and some features of lymphocytic hypereosinophilic syndrome, describes a diagnostic protocol for patients ...
Nair Parameswaran +5 more
doaj +1 more source
Rationale of New Grading System: Central Compartment Atopic Disease
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Central compartment atopic disease (CCAD) has recently been recognized as a distinct phenotype within the spectrum of type 2–dominant chronic rhinosinusitis (CRS). Although international guidelines highlight polypoid changes in the central nasal cavity, standardized diagnostic and classification criteria are still lacking.
Ramón Moreno‐Luna +11 more
wiley +1 more source
Glucocorticoids and Mepolizumab in Eosinophilic Asthma
New England Journal of Medicine, 2014 report that treatment with mepolizumab, a monoclonal antibody against interleukin-5, allowed a modest reduction in the maintenance dose of oral gluco -corticoids in patients who had severe eosino-philic asthma. The absolute reduction in the median dose of prednisone in the mepolizumab group was from 10.0 mg per day to 3.1 mg per day (as compared with a
Bel, E, Ortega, H, Pavord, I
openaire +6 more sources